Patient Monitoring Market Size is Projected to Reach USD 112.47 Billion by 2033, Growing at a CAGR of 7.3%: Straits Research
The global patient monitoring market size was valued at USD 55.60 billion in 2024 and is projected to reach from USD 59.66 billion in 2025 to USD 112.47 billion by 2033, growing at a CAGR of 7.3% during the forecast period (2025-2033).
New York, United States, Jan. 27, 2025 (GLOBE NEWSWIRE) -- A set of instruments known as a patient monitoring system enables medical professionals to monitor a patient's health. These gadgets—remote physiologic monitoring—are routinely used for remote patient monitoring. Utilizing digital technology, they gather and track patient health data, transmit it electronically to healthcare specialists, and use it to aid in condition evaluation, diagnosis, and treatment. This technology alters how healthcare is delivered in the US by reducing costs and improving patient outcomes. Patient monitoring systems are easier to define in terms of their uses.
One well-known example of a patient monitoring system is electrocardiography (ECG), which records the heart's electrical activity. Hypertensive patients use monitoring tools to keep an eye on their blood pressure. People with diabetes utilize glucose monitoring equipment to assess blood glucose levels and prevent potentially dangerous consequences. Patients with chronic obstructive pulmonary disease (COPD), asthma, and other respiratory conditions also require monitoring equipment.
Download Free Sample Report PDF @ https://straitsresearch.com/report/patient-monitoring-market/request-sample
Market Dynamics
Growing Adoption of Remote Patient Monitoring Drives the Global Market
Recent years have seen a significant increase in the usage of patient monitoring devices for continuous vital sign monitoring and analysis, particularly during the COVID-19 outbreak. Patient monitoring systems enable medical personnel to monitor patients' health remotely or at home. Healthcare can become more digitalized to lower costs and boost revenue for medical practices. Additionally, remote monitoring equipment that provided medical treatment in a comfortable setting and permitted remote monitoring from patients' homes was helpful for non-COVID-19 patients who needed chronic care. This increased the number of beds and other important clinical resources available in hospitals and other healthcare facilities for patients who required immediate on-site care.
Due to stringent government regulations and favorable laws for patient monitoring equipment, it is anticipated that many organizations will be motivated to develop novel pharmaceuticals for treating chronic diseases like cardiovascular and respiratory diseases, cancers, diabetes, and chronic respiratory diseases. The widespread use of patient monitoring tools in clinical research trials and the convenience of monitoring is made possible by the market penetration of these tools, which hastens the development of novel medications. The increased prevalence of chronic diseases directly impacts the utilization of ICUs. Due to the benefits offered by patient monitoring devices, such as shorter hospital stays, fewer adverse effects, and speedier recovery times, the market is predicted to grow profitably.
Rising Demand in Non-Hospital Creates Tremendous Opportunities
The sustainability of the current healthcare system is a serious worry for governments worldwide. Due to escalating healthcare expenditures, particularly in hospital settings, the focus has recently switched to alternative treatment modalities, including home healthcare. In addition, the frequency of hospital readmissions has dramatically decreased since the introduction of remote and home monitoring technology. There is consequently a growing demand for effective home medical devices, such as fetal and neonatal monitors, ECG recorders, temperature monitors, pulse oximeters, and event monitors.
Regional Analysis
North America is the most significant patient monitoring market shareholder and is estimated to exhibit a CAGR of 8.1% over the forecast period. 42.7% of the market for patient monitoring devices was in North America. This results from several things: its well-established healthcare infrastructure, high healthcare spending, monopolistic market participants, and the rapid adoption of cutting-edge technologies. North America has the most developed medical equipment market worldwide. The market is anticipated to be driven by the quick adoption of patient monitoring and homecare devices for routine, continuous, and long-term patient monitoring and reducing the number of hospital visits during the projected period.
Additionally, favorable payment terms are expected to accelerate market expansion. Additional factors anticipated to drive market expansion include the rise in accidents, sports injuries, and health problems associated with lifestyle. Increased emergency care needs and increased usage of mobile surgery centers are expected to drive the market during the forecasted period.
Europe is anticipated to exhibit a CAGR of 8.4% over the forecast period. Europe accounted for 25.1% of the global market for patient monitoring devices in 2020. Europe's market includes countries including Germany, France, Italy, Spain, and the United Kingdom. The increasing demand for patient monitoring devices and central data management systems for accurate information and medical services is expected to boost the market. Market expansion is fueled by the prevalence of diseases and the growing older population. In 2020, more than one-fifth of people in Europe were over 65.
In Europe, the leading cause of illness and mortality is chronic disease. The requirement for patient monitoring devices has increased due to the number of patients admitted to healthcare facilities. The COVID-19 pandemic has increased the usage of patient monitoring devices and remote monitoring to assess and analyze vital signs in healthcare settings. To obtain more exact and accurate results economically, advanced patient monitoring devices are constantly being developed and presented by various market participants. As a result, the market for patient monitoring devices is anticipated to grow during the period in question.
Ask for Customization @ https://straitsresearch.com/report/patient-monitoring-market/request-sample
Key Highlights
The global patient monitoring market size was valued at USD 55.60 billion in 2024 and is projected to reach from USD 59.66 billion in 2025 to USD 112.47 billion by 2033, growing at a CAGR of 7.3% during the forecast period (2025-2033).
Based on the product, the global patient monitoring market is bifurcated into blood glucose monitoring systems, cardiac monitoring devices, multiparameter monitoring devices, respiratory monitoring devices, temperature monitoring devices, hemodynamic/pressure monitoring devices, fetal neonatal monitoring devices, neuromonitoring devices, weight monitoring devices, other. The blood glucose segment dominates the global market and is projected to exhibit a CAGR of 9.1% over the forecast period.
Based on end-users, the global patient monitoring market is divided into Hospitals, Ambulatory Surgery Centers, Home Care Settings, and Others. The hospital segment is the most significant contributor to the market and is estimated to exhibit a CAGR of 8.2% over the forecast period.
North America is the most significant global patient monitoring market shareholder and is estimated to exhibit a CAGR of 8.1% over the forecast period.
Competitive Players
Abbott
Boston Scientific
Medtronic
Philips
Nihon Kohden Health Anywhere Inc.
Koninklijke Philips N.V.
G.E. Healthcare
MASIMO CORPORATION
Smiths Medical
Bosch
Biotronik
Intel
Welch Allyn
Recent Developments
In June 2023, With the introduction of its Generation (Gen) 1 device, medical diagnostic company Know Labs provides the first non-invasive glucose monitor. The Generation (Gen) 1 gadget prototype uses radio waves and machine learning algorithms to measure blood sugar levels through the skin.
In May 2023, Royal Philips, a global leader in health technology, and Masimo, a global medical technology company, announced FDA clearance for SedLine® Brain Function Monitoring, Regional Oximetry (O3®), and CO2 measurements in Philips Patient Monitors – IntelliVue MX750 and MX850. The latest extension will let clinicians make quick and informed judgments without additional monitoring equipment.
Segmentation
By Product
Blood Glucose Monitoring Systems
Cardiac Monitoring Devices
Multiparameter Monitoring Devices
Respiratory Monitoring Devices
Temperature Monitoring Devices
Hemodynamic/Pressure Monitoring Devices
Fetal and Neonatal Monitoring Devices
Neuromonitoring Devices
Weight Monitoring Devices
By End-User
Hospitals
Ambulatory Surgery Centers
Home Care Settings
By Region
North America
Europe
Asia-Pacific
Latin America
The Middle East and Africa
Get Detailed Market Segmentation @ https://straitsresearch.com/report/patient-monitoring-market/segmentation
About Straits Research Pvt. Ltd.
Straits Research is a market intelligence company providing global business information reports and services. Our exclusive blend of quantitative forecasting and trends analysis provides forward-looking insight for thousands of decision-makers. Straits Research Pvt. Ltd. provides actionable market research data, especially designed and presented for decision making and ROI.
Whether you are looking at business sectors in the next town or crosswise over continents, we understand the significance of being acquainted with the client's purchase. We overcome our clients' issues by recognizing and deciphering the target group and generating leads with utmost precision. We seek to collaborate with our clients to deliver a broad spectrum of results through a blend of market and business research approaches.
Phone: +1 646 905 0080 (U.S.)
+44 203 695 0070 (U.K.)
Email: sales@straitsresearch.com
Follow Us: LinkedIn | Facebook | Instagram | Twitter
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
CNN
17 minutes ago
- CNN
Kennedy names new members of CDC vaccine advisory panel days after removing previous advisers
Just two days after retiring the entirety of the US Centers for Disease Control and Prevention's vaccine advisory panel, US Health and Human Services Secretary Robert F. Kennedy Jr. has appointed several prominent critics of the government's Covid-19 response to that committee. He announced eight new members of the CDC's Advisory Committee on Immunization Practices, or ACIP, on Wednesday. Kennedy had said Monday that the previous 17-member panel that makes recommendations on who should get vaccines and when was rife with conflicts of interest and that he would appoint new 'highly credentialed' experts in time for the panel's June 25 meeting, at which the members are expected to discuss guidance for Covid-19 and HPV shots, among others. In a statement Wednesday, Kennedy said the reassembled panel will demand 'definitive safety and efficacy data before making any new vaccine recommendations, but will also review data for the current vaccine schedule as well.' The eight new ACIP members include Dr. Robert Malone, a biochemist who made early innovations in the field of messenger RNA but in more recent years has been a vocal critic of mRNA technology in Covid-19 vaccines. The CDC recently narrowed its recommendations for mRNA Covid-19 shots, but some advocates in the Make America Healthy Again space have pressed Kennedy to go further and bar the vaccines entirely. Another new member is Dr. Martin Kulldorff, a biostatistician and epidemiologist who co-authored an October 2020 strategy on herd immunity known as the Great Barrington Declaration with Dr. Jay Bhattacharya, now director of the US National Institutes of Health. Both Malone's and Kulldorff's names were circulated early in the second Trump administration as potential advisers on ACIP or other panels, according to a person familiar with the process who requested anonymity because they weren't authorized to speak with CNN. Kennedy also chose Dr. James Pagano, an emergency medicine physician he described as a 'strong advocate for evidence-based medicine' who has served on hospital committees and medical executive boards. Dr. Retsef Levi, an MIT professor who has published studies on mRNA vaccines and cardiovascular events, is also joining the panel. Levi is a professor of operations management. Several of the new members have served in federal health agencies previously, including Dr. Joseph Hibbeln, a former acting chief of the NIH's section on nutritional neurosciences. Dr. Cody Meissner, a Dartmouth professor of pediatrics who also signed the Great Barrington Declaration, has previously served on ACIP and on the US Food and Drug Administration's Vaccines and Related Biological Products Advisory Committee. Dr. Vicky Pebsworth, the Pacific region director of the National Association of Catholic Nurses, also served on the FDA committee and on a national panel reviewing the 2009 H1N1 swine flu vaccine. Dr. Michael Ross, a professor of obstetrics and gynecology at George Washington University and Virginia Commonwealth University, has previously served on the CDC's Advisory Committee for the Prevention of Breast and Cervical Cancer. Kennedy also nodded in his statement to Ross' 'continued service on biotech and healthcare boards.' The private equity company Havencrest, in which Ross is an operating partner, describes him on its site as a 'serial CEO' who has served on the boards of several biotechnology companies.
CNN
24 minutes ago
- CNN
Kennedy names new members of CDC vaccine advisory panel days after removing previous advisers
Vaccines Federal agencies Respiratory virusesFacebookTweetLink Follow Just two days after retiring the entirety of the US Centers for Disease Control and Prevention's vaccine advisory panel, US Health and Human Services Secretary Robert F. Kennedy Jr. has appointed several prominent critics of the government's Covid-19 response to that committee. He announced eight new members of the CDC's Advisory Committee on Immunization Practices, or ACIP, on Wednesday. Kennedy had said Monday that the previous 17-member panel that makes recommendations on who should get vaccines and when was rife with conflicts of interest and that he would appoint new 'highly credentialed' experts in time for the panel's June 25 meeting, at which the members are expected to discuss guidance for Covid-19 and HPV shots, among others. In a statement Wednesday, Kennedy said the reassembled panel will demand 'definitive safety and efficacy data before making any new vaccine recommendations, but will also review data for the current vaccine schedule as well.' The eight new ACIP members include Dr. Robert Malone, a biochemist who made early innovations in the field of messenger RNA but in more recent years has been a vocal critic of mRNA technology in Covid-19 vaccines. The CDC recently narrowed its recommendations for mRNA Covid-19 shots, but some advocates in the Make America Healthy Again space have pressed Kennedy to go further and bar the vaccines entirely. Another new member is Dr. Martin Kulldorff, a biostatistician and epidemiologist who co-authored an October 2020 strategy on herd immunity known as the Great Barrington Declaration with Dr. Jay Bhattacharya, now director of the US National Institutes of Health. Both Malone's and Kulldorff's names were circulated early in the second Trump administration as potential advisers on ACIP or other panels, according to a person familiar with the process who requested anonymity because they weren't authorized to speak with CNN. Kennedy also chose Dr. James Pagano, an emergency medicine physician he described as a 'strong advocate for evidence-based medicine' who has served on hospital committees and medical executive boards. Dr. Retsef Levi, an MIT professor who has published studies on mRNA vaccines and cardiovascular events, is also joining the panel. Levi is a professor of operations management. Several of the new members have served in federal health agencies previously, including Dr. Joseph Hibbeln, a former acting chief of the NIH's section on nutritional neurosciences. Dr. Cody Meissner, a Dartmouth professor of pediatrics who also signed the Great Barrington Declaration, has previously served on ACIP and on the US Food and Drug Administration's Vaccines and Related Biological Products Advisory Committee. Dr. Vicky Pebsworth, the Pacific region director of the National Association of Catholic Nurses, also served on the FDA committee and on a national panel reviewing the 2009 H1N1 swine flu vaccine. Dr. Michael Ross, a professor of obstetrics and gynecology at George Washington University and Virginia Commonwealth University, has previously served on the CDC's Advisory Committee for the Prevention of Breast and Cervical Cancer. Kennedy also nodded in his statement to Ross' 'continued service on biotech and healthcare boards.' The private equity company Havencrest, in which Ross is an operating partner, describes him on its site as a 'serial CEO' who has served on the boards of several biotechnology companies.
Yahoo
28 minutes ago
- Yahoo
U.S.-born Asian Americans no longer the healthiest group among older adults
For the first time in two decades, older Asian Americans are no longer the healthiest U.S.-born aging racial group with the lowest rates of disability, according to a study published last month in the Journals of Gerontology. The report focused on adults aged 50 and older, and used disability prevalence as an indicator for overall health. The paper shows that while disability rates have decreased among aging adults in every racial group, it's remained unchanged among U.S.-born Asian Americans. The findings suggest that one contributor to the stagnating disability rate is income inequality, which has impacted Asian Americans more than any other group in recent years. Previous research had shown that both foreign-born and U.S.-born Asian older adults had lower mortality and disability rates than their counterparts in other racial groups. According to the new report, non-Hispanic white Americans have overtaken Asians Americans as the healthiest U.S.-born population, with the lowest disability prevalence. 'This study shows that the 'model minority' stereotype is wrong about the overall experience of U.S.-born older Asians in terms of health,' said lead author Leafia Ye, an assistant sociology professor at the University of Toronto. The report is the first to focus solely on the health of U.S.-born Asians, a group that experts say has been understudied due to its limited population size. The study drew on data from the American Community Survey, which has a sample size of more than 18 million U.S.-born adults aged 50 and older. The sample size for U.S.-born Asians is roughly 116,000, Ye said. The study authors defined disability as any chronic physical or mental health condition that limits an older adult's self-care or independent living capacity, which includes carrying out tasks like eating, bathing and grocery-shopping without assistance. Two decades ago, just 5.5% of U.S.-born Asian elders had trouble living independently — compared with 7% of white and 14% of Black elders. From 2005 to 2022, the report found, disability rates fell by at least 2% among U.S.-born non-Hispanic white, Black, Hispanic and Indigenous populations, as well as all foreign-born groups. (Black older adults experienced the largest drop from 14% to 10%.) Among native-born older Asian Americans, however, the rate has stayed at 5.5%. Ye said the trends preceded the Covid-19 pandemic, so it's unlikely that rising anti-Asian racism was a key risk factor. 'What's striking about this study is that U.S.-born Asians are the only group that hasn't experienced improved outcomes,' said Mansha Mirza, principal investigator at the Aging Services Inclusive of Asian American Networks, a national technical assistance and resource development center focused on Asian Americans older adults. Mirza was not involved with the new study. The trend could be attributed to the fact that U.S.-born Asians 'are more assimilated into the American way of life,' Mirza said, while foreign-born Asians were more likely to 'retain practices from their home countries related to nutrition and diet.' Disability prevalence varies across the racial group. Cognitive disability is more prevalent in Vietnamese, Filipino and Japanese older adults, according to a 2024 paper in Innovation in Aging. For self-care disability, on the other hand, Vietnamese, Chinese, Filipino and Indian older adults have a higher prevalence. In the past, older Asian Americans have had better health outcomes than other groups because the large majority were foreign-born, Ye said. People with poorer health and lower socioeconomic status were less likely to resettle in another country, she said, so Asian immigrants became a 'very positively selected' group that's 'healthier and more successful economically compared with both the source and the destination populations.' By contrast, Ye said, U.S.-born Asians were immediately exposed to the country's cultural and political realities. Socioeconomic status has a particularly strong influence on health outcomes, as college-educated older Asian Americans saw a slight decline in disability, while those without a degree saw an increase. While the data didn't contain mental health measures, like loneliness and anxiety, Ye said it's possible that these conditions could have also contributed to stagnating health outcomes. 'In a way,' Ye said, 'U.S.-born Asians are both less selected and more exposed throughout their lifetime.' Mirza said a point of further study could be desegregated research on the impact of migration history on health outcomes. First-generation Vietnamese and Cambodian refugees, for example, survived war, famine and genocide. Research has shown that exposure to these adverse conditions could contribute to 'altered diets and physiological capacity' in their U.S.-born children, who are now advancing in age, Mirza said. Mirza also emphasized a need to study the impact of social isolation on Asian seniors, which she said is gradually emerging as a social determinant of health as much as smoking and alcohol use. 'We need to see what social isolation looks like for foreign-born Asians Americans and U.S.-born Asians Americans,' she said, 'and the extent to which social ties are preserved within these groups.' This article was originally published on
